The<unk>  is an international<unk>  started by Médecins Sans Frontières (MSF) to increase the availability of<unk><unk>  in developing countries. MSF often has difficulties treating patients because the<unk>  required are too expensive or are no longer produced. Sometimes, the only drugs available are highly toxic or ineffective, and they often have to resort to inadequate testing methods to diagnose patients. The lack of research into diseases that affect most of the world’s poor population is known as the 10-90 gap and it occurs because pharmaceutical companies rarely make a profit when developing drugs for these diseases. Although some countries have created legislation to encourage development of<unk>  but commercially ignored<unk> , which are called orphan drugs in the United States, MSF started this<unk>  in November 1999 to bring more awareness to the issue, using its prize money from its 1999 Nobel Peace Prize to fund the project. MSF’s<unk>  is pushing to lower the prices of existing drugs, vaccines and diagnostic tests, to stimulate research and development into new treatments for diseases that primarily affect the poor, and to overcome other barriers that prevent patients getting the treatment they need. The<unk>  is made up of a team of medical, legal, policy and communications specialists working together to tackle these various issues.
Campaign for Access to Essential Medicines
Classification of Pharmaco-Therapeutic Referrals
Connecting Organizations for Regional Disease Surveillance
Vaccination policy
Death Certificate
Public health observatory
International healthcare accreditation
Commission for Certification in Geriatric Pharmacy